Vir Biotechnology, Inc. (VIR)

NMS – Real vaqt narxi. Valyuta: USD

9.40

+0.11 (1.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

9.47

+0.07 (0.74%)

Bozordan keyin: May 12, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Vir Biotechnology, Inc. (VIR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Videolar

No Data

Press-relizlar

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Search stocks

Vir Biotechnology, Inc. (VIR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

Videolar

No Data

Press-relizlar

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer